Orion Oyj
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
652 / 1328
Position in country
140 / 253
Return on Assets, %
15.8
-2.7
Net income margin, %
23.3
2.8
EBITDA margin, %
31.6
10.8
Debt to Equity, %
22.4
19.2
Intangible assets and goodwill, %
13.9
3.6
Revenue CAGR 3Y, %
3.3
8.5
Total Equity change 1Y, %
1
0
Revenue Y, % chg
-7.5
0.5
P/E
21.3
22.7
P/BV
5.2
1.5
P/S
3.9
2.3
EV/S
4
2.4
EV/EBITDA
14.7
7.4
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
156.1
51.3
Forward P/E
19.7
15.6
Dividend Yield, %
2.4
1.7
Expected dividend per share
1.8
0
Payout Ratio, %
103.5
30.3
Dividend Ex Date
2024-03-21
Competitors
Ranks
-
Novo Nordisk A/S
00%
-
Sanofi SA
00%
-
AstraZeneca PLC
00%
-
Eli Lilly and Co
00%
-
Roche Holding AG
00%
-
Orion Oyj
00%
-
Novartis AG
00%
-
Johnson & Johnson
00%
-
Merck & Co Inc
00%
-
Pfizer Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Finland
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
5012.4
Ticker
ORINY.PK
ISIN
US68628Y1047
IPO date
2006-07-03
Availability on Russian exchanges
No
Reporting for
2024-02-26
Date fact. publication of reports
2023-12-31
Company Description
Orion Oyj, previously Orion Corporation, is a Finland-based company active within the pharmaceutical industry. The Company is engaged in the research and development, manufacture and marketing of human and veterinary pharmaceuticals and active pharmaceutical ingredients. The core therapy areas of the Company's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory diseases.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: